Egis Gyogyszergyar

Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Biogal Gyogyszergyar

Egis Gyogyszergyar Zrt.

Egis Gyogyszergynar Nyilvanosan Muekoedoe Reszvenytarsasag

Egis Gyogyszergyat

Laszlo Pongo

Jozsef Barkoczy

Balazs Volk

Lujza E Petocz

Marton Fekete

Istvan Gyertyan

Istvan Gacsalyi

Frigyes Gorgenyi

Jozsef Reiter

Gyula Lukacs

Maria Tothne Lauritz

Gabor Gigler

Tibor Szabo

Adrienn Keszthelyi

Gyorgy Ruzsics

Andras Dancso

Jozsef Debreczeni

Gyula Simig

Eniko Szirt Nee Kiszelly

Gabor Nemeth

Lajos Toldy

Kalman Nagy

Istvan Horvath

Tibor Lang

Ferenc Lorant Bartha

Geza Szilagyi

Maria Szecsey Nee Hegedus

Gyorgy Krasznai

Gyoergy Ruzsics

Judit Broda

Imre Kiraly

Andras Boza

Tamas Somorai

Ede Laszlo Marvanyos

Josef Barkoczy

Josef Reiter

Balazs Peregi

Imre Koehegyi

Maria Kovacs

The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.

Dasatinib salts

The present invention relates to a process for the preparation of dabigatran etexilate of the formula 

Pharmaceutical intermediates and process for the preparation thereof

The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.

Method for preparing rosuvastatin salts

The present invention relates to the use of novel vildagliptin complexes for the manufacture of high purity vildagliptin of Formula I and/or pharmaceutical acceptable salts thereof. Further objects of the present invention are pharmaceutically acceptable complexes of vildagliptin and/or amorphous and crystalline forms, anhydrous forms, amorphous and crystalline hydrates, amorphous and crystalline solvates of the complexes and a process for the preparation thereof. Another object of the present invention is the high purity vildagliptin and pharmaceutically acceptable salts thereof prepared form the vildagliptin complexes of the present invention, a process for the preparation thereof and pharmaceutical compositions containing vildagliptin base, pharmaceutically acceptable salts and/or complexes and use thereof for the treatment of type 2 diabetes (NIDDM). The present invention provides pharmaceutically advantageous high purity vildagliptin complexes.

Inorganic salt complexes of vildagliptin

The invention relates to novel triazolyl thioamides of the general formula (I), ##STR1## wherein Q represents hydrogen or a heterocyclic group optionally bearing one or more C.sub.1-4 alkyl substituent(s), or a group of the formula SR.sup.1, wherein

Triazolyl thioamide derivates

This invention relates to novel triazolyl hydrazide derivatives and a process for the preparation thereof. The new triazolyl hydrazide derivatives of the general formula (I). ##STR1## wherein Q represents hydrogen or a heterocyclic group optionally substituted by a C.sub.1-4 alkyl group; or a group of general formula SR.sup.1, wherein

Triazolyl hydrazide derivatives

The invention relates to acylated 1,2,4-triazole derivatives of general formula I ##STR1## wherein R.sup.1 represents an unsubstituted phenyl group or a phenyl group substituted by one or more halogen atoms, lower alkyl, alkoxy, acyloxy, hydroxy, amino, azido, nitro, trifluoromethyl, lower alkylthio, alkylsulfinyl, or alkylsulfonyl group, and

Antiviral acylated 1,2,4-triazole derivatives

Growing community of inventors

Kerepes, Hungary

Laszlo Pongo